clinical trial · NCT06578585
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
H. Lundbeck A/S·phase1·completed·n = 43
MigraineUbrogepantLu AG09222Placebo
brief summary
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.
started
Sep 13, 2024
primary completion
Jul 11, 2025
completion
Jul 11, 2025
last updated
Oct 14, 2025
official title
Interventional, Randomized, Double-blind, Placebo-controlled Trial Investigating the Safety and Tolerability of Lu AG09222 When Coadministered With Ubrogepant in Participants With Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol